Thank you to everyone who came to the ADOPT Summit 2016. It was great to see people take critical steps to deliver the next generation of CAR-T, TCR, Tregs & NK cell therapies.
Tackling clinical strategy and scalable manufacture to ensure global commercial viability, ADOPT London 2017 will enable you to accelerate discovery, clinical development and economic cost of goods manufacture of adoptive immunotherapies to treat both liquid and solid tumour indications. The agenda for 2017 is already underway. Register your interest to be the first to see it.
"It was great to hear where each company is headed in developing the therapies and how many patients have been enrolled"
- Miltenyi Biotec